Cullinan Oncology
CGEM
143 hedge funds and large institutions have $471M invested in Cullinan Oncology in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 24 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 44
4% less capital invested
Capital invested by funds: $490M → $471M (-$18.1M)
3% less funds holding
Funds holding: 148 → 143 (-5)
4.43% less ownership
Funds ownership: 110.53% → 106.09% (-4.4%)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
99% less call options, than puts
Call options by funds: $101K | Put options by funds: $7.55M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$9.52M |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$1.41M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.1M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$888K |
| 5 |
VC
Voss Capital
Houston,
Texas
|
+$616K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$13.5M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$7.42M |
| 3 |
Millennium Management
New York
|
-$2.19M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$1.95M |
| 5 |
Morgan Stanley
New York
|
-$1.93M |
CGEM Hedge Fund Activity: Q2 2025 in Review
143 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q2 2025, worth a combined $471M — down 3.7% from $490M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CGEM and 20 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 52 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $9.52M. The largest seller was AllianceBernstein, cutting an estimated $13.5M.
- 143 institutional investors held Cullinan Oncology (CGEM) as of Q2 2025, down from 148 in Q1 2025.
- Funds reported $471M of Cullinan Oncology stock for Q2 2025, down 3.7% quarter-over-quarter.
- 20 funds opened new Cullinan Oncology positions in Q2 2025 and 24 closed out, a net change of -4 holders.
- The largest Cullinan Oncology buyer in Q2 2025 was Lynx1 Capital Management, an estimated $9.52M added.
- The largest Cullinan Oncology seller in Q2 2025 was AllianceBernstein, an estimated $13.5M sold.
Based on aggregated 13F filings for Q2 2025.